Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wolfspeed Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B), while Wolfspeed Inc trades at $31.97 (market cap $1.57B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 85.5× Wolfspeed Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| VRTX | WOLF | |
|---|---|---|
Market Cap | $134.25B | $1.57B |
Sector | Health | Technology |
52-Week High | $529.65 | $73.68 |
52-Week Low | $376.62 | $1.19 |
Enterprise Value | $128.37B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.
Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.
WOLF is trading at $32.24, up 10.03% today, showing strong momentum amid a bullish technical outlook. The stock faces fundamental challenges with negative gross (-26.63%) and net (-79.83%) margins, though recent earnings beat expectations in two of the last three quarters. Positive developments include strategic partnerships with LITEON and GE Aerospace for silicon carbide technology in AI data centers and defense applications, driving investor optimism despite profitability concerns.
The outlook is mixed: technical strength and AI/defense partnerships offer upside, but persistent losses and competitive risks warrant caution. Analysts are divided (31.58% Buy, 47.37% Hold), highlighting the stock's high-risk, high-reward profile. Key risks include execution on profitability, patent litigation with Navitas, and reliance on emerging tech adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
